Penumbra closed 2024 on a strong note, driven by robust growth in its U.S. thrombectomy business and the successful introduction of new CAVT products. Despite challenges in the China market and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback